<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04308642</url>
  </required_header>
  <id_info>
    <org_study_id>2019-02143; ks19Pfister</org_study_id>
    <nct_id>NCT04308642</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy</brief_title>
  <acronym>Kid-MaCareOnco</acronym>
  <official_title>Pilot Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy (Kid-MaCare Oncology)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stiftung für Krebskranke Kinder</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate blood and urine kidney injury markers (especially Uromodulin) in
      pediatric cancer patients treated with nephrotoxic chemotherapy. Uromodulin is a marker to
      detect and monitor tubular injury and renal function.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum uromodulin levels (ng/ml)</measure>
    <time_frame>from baseline (i.e. prior to first nephrotoxic chemotherapy cycle) to post-baseline (i.e. at the end of the first nephrotoxic chemotherapy cycle exposure); depending on chemotherapy protocol (maximally 24 - 72 hours)</time_frame>
    <description>Change in serum uromodulin levels (ng/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum uromodulin levels (ng/ml)</measure>
    <time_frame>at baseline (i.e. prior to first nephrotoxic chemotherapy cycle) and post-baseline (i.e. before, dur-ing and at the end of each nephrotoxic chemotherapy cycle),maximally 6- 9 months</time_frame>
    <description>Change in serum uromodulin levels (ng/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine uromodulin levels (ng/ml)</measure>
    <time_frame>at baseline (i.e. prior to first nephrotoxic chemotherapy cycle) and post-baseline (i.e. before, dur-ing and at the end of each nephrotoxic chemotherapy cycle), maximally 6- 9 months</time_frame>
    <description>Change in urine uromodulin levels (ng/ml)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Kidney Impairment</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood test for renal biomarkers</intervention_name>
    <description>blood test for renal biomarkers (uromodulin,Neutrophil gelatinase-associated lipocalin, beta-trace protein, creatinine, cystatin C)</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>urine test for renal biomarkers</intervention_name>
    <description>urine test for renal biomarkers (uromodulin, alpha-1 microglobulin, retinol-binding protein, Neutrophil gelatinase-associated lipocalin (NGAL), beta-trace protein, cylinder, albumin, immunoglobulin G (IgG), transferrin, creatinine)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric cancer patients aged 0-18 years treated at the hematology-oncology at the
        University Children's Hospital Basel (UKBB) with a cancer diagnosis, that indicates a
        nephrotoxic chemotherapy including the drugs High Dose MTX (HD-MTX), ifosfamide, cis- and
        carboplatin.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent by their-selves (≥ 14 years) or their legal representatives (&lt;
             14 years or in case of lacking capacity of judgement)

          -  cancer diagnosis, that indicates a nephrotoxic chemotherapy including the drugs High
             Dose MTX (HD-MTX), ifosfamide, cis- and carboplatin.

        Exclusion Criteria:

          -  critically-ill patients with inotropic and/or vasopressor drugs

          -  signs of severe Sepsis

          -  receiving other nephrotoxic drugs parallel to the chemotherapy cycle
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Pfister, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital Basel (UKBB), University of Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Pfister, Prof MD</last_name>
    <phone>0041 61 704 1851</phone>
    <email>Marc.Pfister@ukbb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tatjana Welzel, MD</last_name>
    <email>Tatjana.Welzel@ukbb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Children's Hospital Basel (UKBB), University of Basel</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc Pfister, Prof. MD</last_name>
      <phone>0041 61 704 1851</phone>
      <email>Marc.Pfister@ukbb.ch</email>
    </contact>
    <investigator>
      <last_name>Tatjana Welzel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas von der Weid, Prof. MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johannes van den Anker, Prof. MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lukas Bubendorf, Prof. MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nephrotoxic chemotherapy</keyword>
  <keyword>pediatric cancer patients</keyword>
  <keyword>renal adverse drug events</keyword>
  <keyword>renal function</keyword>
  <keyword>renal tubular injury</keyword>
  <keyword>Uromodulin</keyword>
  <keyword>drug related kidney injury</keyword>
  <keyword>kidney markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

